The Food and Drug Administration intends to update its Risk Evaluation and Mitigation Strategy requirements for extended-release and long-acting opioid analgesics, and extend the same requirements to immediate-release opioid analgesic products, FDA Commissioner Scott Gottlieb, M.D., announced this week. The existing REMS requires companies that manufacture extended-release and long-acting opioid analgesics to make education programs available to prescribers and patients. According to Gottlieb, the new REMS will modify the prescriber education blueprint to include more information on pain management, safe use of opioid analgesics, addiction medicine and opioid use disorders. The REMS also will require manufacturers to make training available to more than physician prescribers, such as nurses and pharmacists involved in pain management. In addition, he said the agency is exploring whether provider education should be mandatory. According to FDA, about 90% of opioid prescriptions in the U.S. are for immediate-release formulations.

Related News Articles

Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Blog
We must address the racial, ethnic and socioeconomic disparities that increase the risk of negative perinatal outcomes for women of color.
Blog
AHA Executive Vice President Maryjane Wurth previews AHA’s Team Training Conference, where different interdisciplinary groups from diverse health care settings…
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Readmissions penalties for hospitals with the greatest share of dually eligible beneficiaries could fall by an estimated $22.4 million in fiscal year 2019,…
Headline
The Centers for Medicare…